Navigation Links
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
Date:4/23/2009

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone

DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone.

Clonicel is the company's lead compound in a pipeline of products that have shown clinical success in alleviating conditions arising from an overactive adrenergic system, the body's control center for regulating stress and a host of other physiologic functions. The Durham-based specialty pharmaceutical company is also developing drugs to treat hypertension, menopausal flushing and potentially insomnia, pain, and migraines.

Based on the positive data from two Phase 3 trials conducted on Clonicel, Addrenex plans to seek approval from the U.S. Food and Drug Administration later this year for Clonicel as both a monotherapy and as an add-on therapy to stimulant medication for children and adolescents with ADHD. The North American rights to market Clonicel are licensed to Sciele Pharma, a Shionogi Company, which is an Atlanta-based specialty pharmaceutical company.

"Our data from the first phase 3 study strongly suggest that Clonicel is an effective therapy for ADHD when used alone, and now we have evidence from a second study that Clonicel also has a complementary effect when used with stimulants," said Moise Khayrallah, Ph.D., CEO of Addrenex Pharmaceuticals. "In children who are not receiving optimal benefit from stimulants such as methylphenidate or amphetamine, Clonicel may provide greater relief than using a stimulant medication alone."

The current study of 200 children with ADHD is the second phase 3 trial in a year
'/>"/>

SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
2. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
5. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
6. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
7. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
8. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
9. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Strativa Pharmaceuticals Provides Product Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24 de mayo de 2013  Volcano Corporation ... y fabricante de herramientas de precisión para terapia ... de la enfermedad vascular periférica y coronaria, anunció ... Ad enosine V asodilator I ndependent ... la sesión de ensayo clínico hot line late ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... 2013 Amgen (NASDAQ: AMGN ) will ... Conference on Thursday, May 30, 2013, at the Westin Boston ... a.m. Eastern Daylight Time. Arvind Sood , ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 Onlinefitnessreview.com ... Belly Blast Diet to determine what makes this diet ... The published review highlights three main components of the ... achieving a positive mindset and the personal motivation that ... intake every 7 days to keep the metabolism rate ...
(Date:5/23/2013)... Vinci surgical robot maker Intuitive Surgical defeated negligent training ... according to Bloomberg.* The Rottenstein Law Group LLP, which ... disappointment in the ruling but encourages those looking to ... verdict as representative of all da Vinci lawsuits. , ... Surgical Inc.; 09-2-03136-5, Superior Court, Port Orchard, Wash.) focused ...
(Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Glucosamine supplements ... and knee osteoarthritis may have an unexpected side effect: ... new study of older adults suggests. Glaucoma ... (IOP) or pressure inside the eye. Left untreated, glaucoma ... In the new study of 17 people, ...
(Date:5/23/2013)... May 23 (HealthDay News) -- A modified version ... fight brain tumors, preliminary research suggests. Scientists ... therapy, known as PVSRIPO, uses an engineered form ... cells, but attacks cancer cells. The therapy shows ... common and aggressive brain tumor, they said. ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2
... Warwick Medical School found that premature babies face a greater ... included 120,000 children born between 1983 and 2001. The findings ... and were born premature are more often placed on the ... were born before 34 weeks. The findings were penned down ...
... Siteman Cancer Center are a part of the new ... Medicine's Medical Photography, Illustration and Computer Graphics (MedPIC) department. ... and their families to paint a 4-inch square ceramic ... have been painted in this manner. These unique artworks ...
... for a appointment a local clinic now you can take ... 10 minutes//, ,Chlamydia is the most common sexually transmitted ... can be passed on to others without knowing. However, complications ... pregnancy and infertility in both men and women., ,The ...
... group jogging or jogging with a friend will be more ... ,Researchers led by Professor Elizabeth Gould at Harvard University compared ... exercise in a group and found that contrary to accepted ... reported online edition of Daily Mail. ,The researchers ...
... the kingdom was untouched by the avian flu disease. // ... of both the public and the government. He said that there ... , The minister made the remarks during a ... that occasion to celebrate this great achievement the people were served ...
... in the majority of the cases is caused by viral ... could be prevented by vaccination. // Cancer of cervix, liver, ... leukemia are thought to be caused by viruses. Stomach cancer ... Campaign said that viruses can trigger the disease in combination ...
Cached Medicine News:Health News:Home Chlamydia Test 2
... Stereo Cube is used to diagnose Stereo and ... use of polarized glasses. The test can ... stereopsis, visual attention, form and depth perception. The ... to 450 seconds of arc and is ideal ...
The Lang Stereotest was created to simplify stereopsis screening in children. It is based on two principles: random dots and cylindrical gratings. The Lang Stereotest I measures disparities: Star 600...
... test was developed to test for both crossed ... the more reliable red/green glasses to provide ... dependent on polarizing spectacles which can be quite ... attractive image of a butterfly which makes the ...
... to assist patients with red-green color deficiencies in ... off wavelengths shorter than 582 nm enabling an ... most difficult color distinctions. A color anomalous patient ... a color is in the longer or shorter ...
Medicine Products: